Publications by authors named "M C Boelens"
Article Synopsis
- - The study investigates mechanisms of resistance in patients with EGFR mutated non-small cell lung cancer (NSCLC) who progressed on osimertinib treatment, using paired plasma and tumor samples for analysis.
- - Out of 51 patients, the driver mutation was found in 82% of plasma samples and 98% of tumor samples, with a concordance rate of 80%, while resistance mechanisms (RMs) were identified in 80% of patients.
- - The findings suggest that analyzing both plasma and tumor samples provides a more comprehensive understanding of osimertinib resistance, with plasma identifying 61.5% and tumor analysis revealing 75% of RMs, leading to better treatment strategies.
Background: Working in healthcare often involves stressful situations and a high workload, and many healthcare workers experience burnout complaints or suffer from mental or physical problems. This also affects the overall quality of health care. Many previous workplace interventions focused on knowledge exchange instead of other health cognitions, and were not particularly effective.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the challenges of diagnosing and treating leptomeningeal metastases (LM) in patients with EGFR mutation positive non-small cell lung cancer (NSCLC) who are being treated with osimertinib, focusing on identifying resistance mechanisms in cerebrospinal fluid (CSF) and plasma.
- A group of 28 patients was analyzed, with a high detection rate of the driver mutation in CSF, but resistance mechanisms were found in 27%, indicating limitations in treatment options available at this time.
- After four weeks on an escalated osimertinib dosage, many patients showed stabilization or worsening of symptoms, suggesting that while some had radiological improvement, overall clinical efficacy remains
Detection of peritoneal dissemination (PD) in gastric cancer (GC) patients remains challenging. The feasibility of tumor-guided cell-free DNA (cfDNA) detection in prospectively collected peritoneal fluid (ascites and peritoneal lavage) was investigated and compared to conventional cytology in 28 patients. Besides conventional cytology, next generation sequencing was performed on primary tumor DNA and cell-free DNA from peritoneal fluid.
View Article and Find Full Text PDFArticle Synopsis
- Oncology is shifting towards genome-driven practices, but most cancer diagnostics still rely on traditional microscopy methods, creating delays in using new genomic biomarkers for patient treatment.* -
- Whole-genome sequencing (WGS) can improve diagnostics by detecting numerous genomic changes in one cost-effective test, and it has been shown to be feasible and valid in a clinical setting, with results provided in about 11 workdays.* -
- Successful WGS implementation, such as at the Netherlands Cancer Institute, requires a detailed protocol addressing sample handling and integration into clinical workflows to overcome challenges faced by pathology labs using conventional sample methods.*